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ABSTRACT 
Pleomorphic adenoma gene (PLAG) 1, the main translocation target in pleomorphic adenomas of the salivary 
glands, is a member of a new subfamily of zinc finger proteins comprising the tumor suppressor candidate 
PLAG-like1 (also called ZAC1 or lost on transformation 1) and PLAGL2. In this report, we show that NIH3T3 
cells overexpressing PLAG1 or PLAGL2 display the typical markers of neoplastic transformation: (a) the cells 
lose cell-cell contact inhibition; (b) show anchorage-independent growth; and (c) are able to induce tumors in 
nude mice. In contrast, PLAGL1 has been shown to prevent the proliferation of tumor cells by inducing cell 
cycle arrest and apoptosis. This difference in function is also reflected in their DNA binding, as we show here 
that the three PLAG proteins, although highly homologous in their DNA-binding domain, bind different DNA 
sequences in a distinct fashion. Interestingly, the PLAG1- and PLAGL2-induced transformation is accompanied 
by a drastic up-regulation of insulin-like growth factor-II, which we prove is a target of PLAG1 and PLAGL2. 
This strongly suggests that the oncogenic capacity of PLAG1 and PLAGL2 is mediated at least partly by 
activating the insulin-like growth factor-II mitogenic pathway. 
Abbreviations : PLAG, pleomorphic adenoma gene; IGF, insulin-like growth factor; ORF, open reading frame; 
β-gal, β-galactosidase; EMSA, electrophoretic mobility shift analysis; IGF-I-R, type 1 insulin-like growth factor. 
 
INTRODUCTION 
Pleomorphic adenoma of the salivary gland is a benign epithelial tumor, which usually arises as a result of 
activation of the PLAG1 gene on chromosome 8q12 (1). In most cases, this activation results from recurrent 
chromosomal translocations that lead to promoter substitution between PLAG1, a gene mainly expressed in fetal 
tissue, and more broadly expressed genes. The three translocation partners characterized thus far are the β-
catenin gene (1), the leukemia inhibitory factor receptor gene (2), and the elongation factor SII gene (3). 
Breakpoints invariably occur in the 5' noncoding part of the PLAG1 gene, leading to an exchange of regulatory 
control elements while preserving the PLAG1 coding sequence. The replacement of the PLAG1 promoter, which 
is inactive in adult salivary glands, by a strong promoter derived from the translocation partner, leads to ectopic 
expression of PLAG1 in the tumor cells. This abnormal PLAG1 expression presumably results in a deregulation 
of PLAG1 target genes, causing salivary gland tumorigenesis. 
We demonstrated recently that PLAG1 is a genuine transcription factor that binds a bipartite element containing 
a Core sequence, GRGGC, and a G-cluster, RGGK, separated by seven random nucleotides. Potential PLAGl-
binding sites were found in promoter 3 of the human IGF-II gene. Remarkably, IGF-II transcripts deriving from 
the P3 promoter are highly expressed in salivary gland adenomas overexpressing PLAG1, whereas they are not 
detectable in adenomas without abnormal PLAG1 expression or in normal salivary gland tissue. This suggests 
that IGF-II could be a PLAG1 target gene (4). 
Two novel cDNAs encoding C2H2 zinc finger proteins, PLAGL1 and PLAGL2, which show high homology to 
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PLAG1, have been identified, constituting by this way a novel subfamily of zinc finger proteins (5). PLAGL1 
has also been isolated independently and referred to as LOT1 and ZAC1 (6, 7). The homology between these 
three PLAG proteins resides mainly in their NH2-terminal zinc finger domain (73% and 79% identity for 
PLAGL1 and PLAGL2, respectively), whereas the COOH-terminal region is much more divergent. Although 
PLAGL1 show high homology to PLAG1 in the DNA-binding domain, the DNA-binding specificities of these 
two proteins seem to differ slightly. Indeed the consensus binding site for PLAGL1 has been identified as the 
sequence GGGGGGCCCC (8). This sequence contains the extended PLAG1 core GGRGGCC but does not 
include the G-Cluster 7 nucleotides downstream. A second difference between these two related factors is that 
PLAG1, when consistently overexpressed in pleomorphic adenomas, is thought to act as a proto-oncogene, 
whereas PLAGL1 seems to act as a tumor suppressor gene. Indeed, expression of PLAGL1 prevented 
proliferation of tumor cells as measured by colony formation, growth rate, and cloning in soft agar, and 
precluded tumor formation in nude mice (7, 8). Moreover it encodes a protein that regulates apoptosis and cell 
cycle arrest (7), maps to a chromosomal region frequently lost in cancer (6), and a decrease or loss of expression 
has been observed in breast tumors (9). 
To determine whether PLAG1 is a genuine proto-oncogene, we evaluated the in vitro transforming capacity of 
PLAG1 by analyzing the growth profile of NIH3T3 cells overexpressing PLAG1, their ability to form foci, to 
grow in soft agar, and to form tumors in nude mice. These analyses were extended to PLAGL1, the third member 
of the PLAG family. Both PLAG1 and PLAGL2 are able to transform NIH3T3 cells and, therefore, can be 
considered proto-oncogenes. Furthermore, by investigating the DNA binding specificities of the PLAG proteins 
and comparing their mode of DNA recognition, we demonstrate that PLAG1 and PLAGL2 have 
indistinguishable binding capacities, which are different from that of PLAGL1. Their similar binding capacities 
are reflected in their ability to induce common target genes; we prove here that IGF-II is a common target of 
PLAG1 and PLAGL2. Moreover, the transformation of NIH3T3 cells by these factors is accompanied by a 
drastic up-regulation of IgfII expression, suggesting that PLAG1 and PLAGL2 stimulate cell proliferation by 
activating the IGF-II mitogenic pathway. 
MATERIALS AND METHODS 
Plasmid Construction. pCDNA3-FLAG-PLAG1 (=pKH26) was constructed by ligating in frame the MscI/XhoI 
fragment isolated from the pCDNA3-PLAG1 expression construct (4) into pCDNA3.1FLAG (a kind gift of 
Stefan Pype of the laboratory of Cell Growth, Differentiation and Development, KUL, VIB). This enables 
expression of a chimeric protein containing the FLAG epitope fused to amino acids 2-500 of PLAG1. The 
complete PLAGL2 ORF except the first ATG was amplified using pyrococcus furiosus (pfu) DNA polymerase 
(Stratagene) with the sense primer P3N2 (5'CCCGAATTCTGACCACATTTTTCACCAGCG3') and the 
antisense primer P3C496 (5'TTTCCATCAAGCATTCCAGTAGCTCGAG3')∙ The PCR product was cloned in 
frame into the pCDNA3.1FLAG vector (=pKH32). pMSCV-FLAG-PLAG1 and pMSCV-FLAG-PLAGL2 were 
constructed by cloning a blunt NheI/XbaI fragment of pKH26 or pKH32 into the HpaI site of the pMSCVpuro 
retroviral vector, respectively (kindly provided by Jan Cools, CME and KUL, and described by Ref. 10). 
The PLAG1 expression construct pCDNA3-PLAG1 has been described elsewhere (4). Expression plasmids 
pCDNA3-PLAGL1 and pCDNA3-PLAGL2 were constructed by inserting into EcoRI-XhoI digested pCDNA3 
(Invitrogen) the complete ORFs of PLAGL1 or PLAGL2 including their own Kozak consensus translation start 
site. These fragments were generated by PCR using pfu polymerase (Stratagene) with the 5' primer P2N-3              
(5'-CCCGAATTCGCAAAGC-CCATGGCCACGTTC-3') and the 3' primer P2C463 (5'-GGGCTCGAGT-
TATCTGAATGCATGATGGAAATGAG-3') for PLAGL1 and with the 5' primer P3N-3                                        
(5'-CCCGAATTCAGCCTTGCCATGACCACATTT-3') and the 3' primer P3C496                                                   
(5'-GGGCTCGAGCTACTGGAATGCTTGATGGAAA-3') for PLAGL2. The three mutant PLAG cDNAs 
(PLAG1-F3mut, PLAGL1-F3mut, and PLAGL2-F3mut) were produced by altering the first codon for the 
histidine in the C2H2 motif of the corresponding zinc finger to that for alanine. This was performed using the 
QuickChange Site-directed Mutagenesis kit (Stratagene) according to the instructions of the supplier. The pSAR-
MT- FLAG-PLAG1 and pSAR-MT-FLAG-PLAGL2 constructs were generated by inserting the NheI/ XbaI-
blunted fragments of pKH26 and pKH32, respectively, into the blunted BamHI site of the pSAR-MT vector (11). 
(WT2)3-TK-luc and (mCLUmCO2)3-TK-luc have been obtained by inserting three copies of the corresponding 
double-stranded oligonucleotides WT2 and mCOmCLU2 (4) into pTK81luc (12). All of the constructs were 
sequenced to confirm the fidelity of the PCR and the site-specific mutagenesis. 
Cell Lines. The human fetal kidney epithelial cell line 293 (ATCC CRL 1573) was cultured according to the 
suppliers' protocols. Inducible PLAG1-, PLAGL2-, and β-gal-expressing cell lines were obtained by transfecting 
293 cell line with 2 µg of pSAR-MT-FLAG-PLAG1, pSAR-MT-FLAG-PLAGL2 or pSAR-MT-β-gal (11), 
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respectively, together with 400 ng of the neomycin resistance vector pCDNA3 using FuGENE 6 Transfection 
Reagent (Boehringer Mannheim) according to the manufacturer's protocol. After 10 days, selection with G418 
(Life Technologies, Inc.) at a concentration of 700 µg/ml, individual clones were isolated and expanded. 
Individual colonies were screened for zinc-inducible expression of PLAG1, PLAGL2, or β-gal by Western blot 
analysis. Cells were induced with 100 µM of ZnCl2 for 16 h. 
The pMSCV retroviral constructs were cotransfected with the pIK 6.1 Ecopac vector (kindly provided by Jan 
Cools, CME, KULeuven), coding for the gag, pol, and env viral proteins, in 293T cells using Superfect (Qiagen) 
according to the manufacturer's protocol. After transfection (48 h), 1 ml of the supernatant containing 
replication-incompetent retroviruses was used to infect NIH3T3 cells (ATCC CRL1658). Cells expressing the 
gene of interest were obtained after 2 days culturing under puromycin selection. 
Western Blot Analysis. Cells were harvested in PBS/EDTA. The cell pellets were lysed in SDS-PAGE sample 
buffer [60 mM Tris-HCl (pH 6.8), 12% glycerol, and 4% SDS], and sonicated. Samples containing equal protein 
amounts were heated at 95°C for 5 min, and were electrophoresed in a 10% polyacrylamide gel and blotted onto 
nitrocellulose membranes. FLAG-tagged proteins were detected with a mouse anti-FLAG monoclonal antibody 
(SIGMA; 0.8 µg/ml) followed by a peroxidase-labeled rabbit α-mouse polyclonal antibody (PROSAN; DAKO; 
0.4 µg/ml). Blots were revealed using the Renaissance detection kit (NEN Life Science Products) according to 
the supplier's instructions. 
Transfections and Luciferase Assay. The puromycin-resistant cells, obtained after infection with recombinant 
retroviruses or empty pMSCV vectors, were plated in six-well plates. The next day, they were transiently 
cotransfected in triplicate with 400 ng of (WT2)3TKluc or (mCLUmCO2)3TKluc reporter plasmids together with 
the Rouse sarcoma virus β-gal DNA as internal control using 3 µl of FuGENE 6 Transfection Reagent 
(Boehringer Mannheim) according to the manufacturer's protocol. Cells were harvested 40 h after the 
transfection and luciferase activity measured using a Monolight 2010 luminometer (Analytical Luminescence 
Laboratory). 
Preparation of RNA and Northern Blot Analysis. Total RNA was extracted using the guanidine thiocyanate 
method (13). Northern blot analysis was performed according to standard procedures. For filter hybridizations, 
probes were radiolabeled with α[32P]dCTP using the megaprime DNA labeling system (Amersham). A 1.5-kb 
cDNA probe containing the complete PLAG1 or PLAGL2 ORF was used for the detection of the respective 
transcripts. A probe containing exon 6 of the mouse IgfII, which is common to the different transcripts generated 
by the three different promoters, was generated by PCR using sense primer mIgfII-up 
(5'CAGATACCCCGTGGGCAAGTTCTTC-CAATA3') and antisense primer mIgfII-low 
(5'TGAAGGGGGGGGGGCGC-CGAATTATTTGA3')- The human IGF-II exon 9 probe, common to the four 
different transcripts P1, P2, P3, and P4, was generated by PCR and contained nucleotides 7970-8774 of the 
published gene sequence (Ref. 14; GenBank/European Molecular Biology Laboratory; accession no. X03562). A 
human IGF-II exon 5 probe specific for the P3 transcript was a kind gift of Dr. P. E. Holthuizen. The lacZ probe 
was generated by isolation of a 2.3-kb ClaI-EcoRI fragment from SDKlacZpA (Ref. 15; kindly given by Dr. J. 
Rossant). 
EMSA. The full-length PLAG proteins as well as the mutants were expressed by in vitro transcription and 
translation using the TNT kit (Promega). Quality of translation was monitored by SDS PAGE analysis of 
[35S]Met-labeled proteins. The EMSAs were performed as described previously (4) and 3 µl of translation 
reaction products were used per lane. 
Focus Formation Assay. Puromycin-resistant cells, obtained after infection with recombinant retroviruses, were 
plated at a density of 3 × 105 cells in a 60-mm tissue culture dish and grown in DMEM/F12 medium 
supplemented with 10% or 1% FCS and puromycin. Medium was changed every 2 or 3 days, and foci of densely 
growing cells appeared after 2-3 weeks. Some of the foci were cloned and grown to mass culture for RNA and 
protein analysis. 
Cell Proliferation Assay. Puromycin-resistant cells, obtained after infection with recombinant retroviruses, 
were plated at a density of 1 × 105 cells in a 60-mm tissue culture dish and cultured in of 5% or 1% FCS. Cells 
were counted every day for 10 days using a Coulter counter. 
Soft Agar Assay. Puromycin-resistant cells (1 × 105), obtained after infection with recombinant retroviruses, 
were resuspended in 2 ml 0.3% agar/DMEM/15%FCS and plated on a base of 0.6% agar/DMEM/15% FCS in 
six-well plates. After 5 days the cells were fed with a fresh agar overlay in DMEM containing 15% FCS. 
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Colonies were counted 3 weeks after plating. 
Tumorigenicity in Nude Mice. Tumorigenicity was evaluated by injecting the puromycin-resistant cells, 
obtained after infection with recombinant retroviruses carrying pMSCV-FLAG-PLAG1, pMSCV-FLAG-
PLAGL2, or empty pMSCV vectors (5 × 106 cells in 0.1 ml PBS) s.c. into both flanks of athymic nude mice. 
The mice were examined for tumor development once a week for 2 months. All of the tumors were clearly 
macroscopically visible within 3-4 weeks after inoculation. Mice were sacrificed after 5 weeks, and the tumors 
were excised for RNA extraction or histological analysis. 
RESULTS 
PLAGL1 Binds a Different Consensus Sequence than PLAG1 and PLAGL2. To compare the DNA-binding 
specificities of the PLAG proteins, we performed EMSA analysis on double-strand probes containing either the 
PLAG1 consensus binding site (WT2 probe), the PLAGL1 consensus binding site (zac probe; Ref. 8), or on five 
mutated probes (see Fig. 1). The proteins used for this study were full-length PLAG proteins translated in vitro 
in reticulocyte lysates. As shown in a previous study (4), we found that PLAG1 binds strongly to the PLAG1 
consensus-binding motif (Fig. 1A, Lane 1). Mutations in the G-cluster reduce drastically the binding (Fig. 1A, 
Lane 2), whereas destruction of the Core abolishes it (Fig. 1A, Lane 3) as do mutations in both (Fig. 1A, Lane 4). 
The distance between the G-cluster and the Core was also shown to be important, as PLAG1 only binds weakly 
to a probe containing the G-cluster separated by 2 bp instead of 7 bp from the Core (Fig. 1A, Lane 5). In contrast, 
the binding of PLAG1 to the zac probe (Fig. 1A, Lane 6) is much less efficient than to the WT2 probe. A similar 
binding profile is observed with PLAGL2 (Fig. 1C, Lanes 1-7) suggesting that PLAGL2 has binding capacities 
comparable with PLAG1. In contrast, PLAGL1 show different binding specificities, as it binds more efficiently 
to the zac probe than to the WT2 probe (compare Fig. 1B, Lane 6 to Lane 1). Moreover, mutations in the cluster 
of WT2 only slightly affect PLAGL1 binding (Fig. 1B, Lane 2), suggesting that a G-cluster is not critical for the 
binding of PLAGL1. This hypothesis is corroborated by the fact that the zac probe does not contain any G-
cluster. Mutations in the core motif of the PLAG1 consensus, on the other hand, completely prevent the binding 
of PLAGL1 (Fig. 1B, Lane 3) as well as mutations in the core of the zac probe. Comparable results were also 
obtained using chimeric proteins containing the complete zinc finger domain of PLAG proteins fused in-frame to 
glutafhione S-transferase (data not shown). All of these results indicate that both motifs, the core and the G-
cluster, are critical for PLAG1 and PLAGL2 binding, whereas only the core motif is recognized by PLAGL1. 
Fingers 3 of PLAG1 and PLAGL2 but not of PLAGL1 Are Critical for the DNA-binding Capacities. We 
have shown recently that finger 3 of PLAG1 interacts with the G-cluster, whereas the core is recognized by 
fingers 6 and 7 (4). As the G-cluster is critical for the binding of PLAG1 and PLAGL2 but not for PLAGL1, we 
were interested in determining whether finger 3 could play different roles in these three proteins. To answer this 
question, we produced mutant PLAG proteins where finger 3 was destroyed by replacing the first histidine of the 
C2H2 motif with an alanine. This mutation hinders the coordination of zinc and has been shown to prevent the 
formation of a functional zinc finger (16). The destruction of finger 3 in PLAG1 and in PLAGL2 drastically 
reduces the affinity of these proteins for the WT2 probe (compare Lanes 8 with Lanes 1 in Fig. 1, A and C). The 
specificity is also completely modified because the F3mut protein binds equally well to WT2, mCLU2, and 
WT2ml (Lanes 9, 10, and 12 in Fig. 1, A and C). Moreover, the F3mut binds preferentially to the zac probe 
compared with the WT2 probe (compare Lanes 13 and 8 in Fig. 1, A and C). These results indicate that, as for 
PLAG1, finger 3 of PLAGL2 is required for interaction with the G-cluster. On the contrary, destruction of finger 
3 of PLAGL1 does not affect the binding specificity of this protein and only slightly decreases its affinity 
(compare Lanes 8-14 in Fig. 1B with Lanes 1-7). This indicates that in contrast to PLAG1 and PLAGL2, finger 3 
of PLAGL1 is not directly involved in DNA recognition. 
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Fig.  1. PLAGL1 binds a different consensus sequence to PLAG1 and PLAGL2. EMSAs were performed with 
recombinant PLAG proteins produced in vitro in reticulocyte lysates. PLAG proteins were incubated with the 
probes WT2 (Lanes 1 and 8), mCLU2 (Lanes 2 and 9), mCO2 (Lanes 3 and 10), mCLUmCO2 (Lanes 4 and 11), 
WT2m1 {Lanes 5 and 12), Zac (Lanes 6 and 13), and Zac mut (Lanes 7 and 14) as described in "Materials and 
Methods." Equal efficiencies of protein expression were obtained for the different constructs as demonstrated by 
SDS-PAGE of proteins labeled with [35S]methionine (data not shown). The percentage of binding of the PLAG 
proteins to the different probes were compared with the binding of the wild-type PLAG to the probe WT2 and are 
the means of at least two experiments. *, a band attributable to binding to the WT2 probe of a protein present in 
the reticulocyte lysate. 
 
 
NIH3T3 Cells Infected with Retrovirus-containing Human PLAG1 and PLAGL2 cDNAs Express High 
Levels of Functional Proteins. To generate NIH3T3 cell lines overexpressing PLAG1 and PLAGL2, we 
infected the cells with the pMSCV retroviral vector encoding FLAG-tagged human PLAG1 or PLAGL2. Empty 
pMSCV vector was used as a negative control. Positive transformants were obtained by puromycin selection and 
checked for gene expression by Northern blot and Western blot analyses. As shown on Fig. 2A, the exogenous 
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PLAG1 and PLAGL2 messages expressed from the viral 5' long terminal repeat could be detected as a 4-kb 
transcript in infected cells (Fig. 2A, Lanes 2 and 4, respectively) but not in mock infected control cells (Fig. 2A, 
Lanes 1 and 3). These are clearly overexpressed compared with the endogenous transcripts. The endogenous 
PLAG1 transcript is visible as a 7.5-kb band (Fig. 2A, Lanes 1 and 2), whereas the endogenous PLAGL2 
transcript, which is also expected to be 7.5 kb, was undetectable (Fig. 2A, Lanes 3 and 4), suggesting extremely 
low expression, if any, of endogenous PLAGL2. Western blot analysis was performed to detect the presence of 
PLAG1 and PLAGL2 recombinant proteins in infected NIH3T3 cells (Fig. 2B). A Mr 56,000 and a Mr 50,000 
protein corresponding to PLAG1 (Fig. 2B, Lane 1) and PLAGL2 (Fig. 2B, Lane 3), respectively, were present in 
infected cells but absent in mock-infected control cells (Fig. 2B, Lane 2). These proteins were shown to be 
functional, because PLAG1- and PLAGL2-overexpressing cells can stimulate the luciferase activity of a reporter 
construct containing three copies of the consensus binding site (WT2)3-TK luc (27- and 10-fold, respectively; 
Fig. 2C). This stimulation is completely abolished when the core and cluster are mutated (mCOmCLU). In 
contrary, mock-infected cells only slightly induced the (WT2)3-TK luc reporter construct (~2.5-fold). This 
induction is probably because of endogenous PLAG1 present in the NIH3T3 cells. 
Al of these data indicate that infected NIH3T3 cells produce high level of functional PLAG1 and PLAGL2 
proteins. Moreover, it is the first demonstration that PLAGL2 is also a genuine transcription factor. 
 
Fig. 2. NIH3T3 cells infected with recombinant retrovirus containing human PLAG1 or PLAGL2 express high 
levels of functional protein. A, total RNA from NIH3T3 cells infected with control virus (Lanes 1 and 3), human 
Flag-PLAG1 retrovirus (Lane 2), and human Flag-PLAGL2 retrovirus (Lane 4) were hybridized with a 32P-
labeled human PLAG1 cDNA (Lanes 1 and 2) or with a 32P-labeled human PLAGL2 cDNA (Lanes 3 and 4). 
Expression of β-actin monitored the integrity and yield of RNA. B, Western blot analysis of whole cell lysates 
from NIH3T3 cells infected with Flag-PLAG1 retrovirus (Lane 1), control retrovirus (Lane 2), and Flag-
PLAGZ2 retrovirus (Lane 3) using an α-FLAG mouse monoclonal antibody. C, PLAG1 and PLAGL2 can 
stimulate transcription through the binding to the consensus sequence WT2. Mock-, PLAG1-, and PLAGL2-
expressing NIH3T3 cells were transfected with 400 ng of the (mCOmCLU2)3 TK-luc reporter construct ( ) and 
400 ng of the (WT2)3TK-luc reporter construct (■), respectively. Rous Sarcoma Viral promoter-β-gal (200 ng) 
was cotransfected as internal control. The results correspond to the mean of the corrected luciferase value of at 
least two independent transfections performed in triplicate; bars, ±SE. 
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Mitogenic Stimulation of NIH3T3 Cells Overexpressing 
PLAG1 and PLAGL2. Transformed cells, unlike normal cells, are able to proliferate in culture medium 
containing low levels of serum, because they have become independent of growth factors. To prove that PLAG1 
and PLAGL2 are transforming factors, we investigated the growth of NIH3T3 cells overexpressing PLAG1 and 
PLAGL2 in low serum culture conditions. Fig. 3A shows the growth curve of a population of cells grown in 5% 
FCS. The proliferation rate of cells overexpressing PLAG1 and PLAGL2 was significantly higher than mock-
infected NIH3T3 cells (~3-fold for PLAG1- and 2.5 fold for PLAGL2-expressing cells). The effect was even 
more striking when cells were cultured in 1% FCS. PLAG1- and PLAGL2-expressing cells proliferate, whereas 
mock-infected NIH3T3 cells are unable to grow (Fig. 3B). The PLAG1-overexpressing cells consistently show 
higher growth rates than the PLAGL2-expressing cells. These data suggest that NIH3T3 cells over-expressing 
PLAG1 and PLAGL2 behave like transformed cells and lose dependence on growth factors present in FCS. 
 
Fig. 3. The mitogenic stimulation of NIH3T3 cells overexpressing PLAG1 and PLAGL2. Mock-, PLAG1-, and 
PLAGL2-expressing NIH3T3 cells were grown in DMEM supplemented with either 5% (A) or 1% (B) FCS and 
counted daily. After 7 days, PLAG1-and PLAGL2-expressing cells reached a maximum cell density. The data 
correspond to the mean of three independent experiments; bars, ±SE. 
 
 
Overexpressed PLAG1 and PLAGL2 Proteins Are Able to Transform NIH3T3 Cells. To evaluate the 
transforming activity of PLAG1 and PLAGL2 when overexpressed, infected cells were grown as a monolayer to 
confluence in medium containing either 1% or 10% serum, and the formation of foci was analyzed (Fig. 4A). 
Contact inhibition of growth was lost leading the cells to pile up and form foci. Cells in the foci presented 
various morphologies, ranging from an elongated shape at the foci border to a rounded and refractile appearance 
in the center. PLAG1-expressing cells seemed to have a higher efficiency in forming foci than PLAGL2-
expressing cells (Fig. 4A and B); foci appeared sooner and became much bigger. Foci were more rapidly 
observed in cells grown in medium containing 1% serum. In contrast, mock-infected NIH3T3 cells in both FCS 
concentrations exhibited contact inhibition and formed no foci. To test if PLAG1- and PLAGL2-mediated effects 
on growth and transformation are dependent on their DNA binding activity, we made retroviral constructs of 
PLAG1 and PLAGL2 containing a mutation in finger 7 to destroy their binding to DNA (4). NIH3T3 cells were 
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infected with these retro-viruses, and focus-forming assay was performed. Transformation of the NIH3T3 cells 
was almost completely abolished supporting the hypothesis that the transformation is caused by binding and 
subsequently activation of the target genes of PLAG1 and PLAGL2 (data not shown). 
The cell lines overexpressing PLAG1 and PLAGL2 were also tested for anchorage-independent growth, another 
tumorigenic feature. For this, cells were seeded in a soft agar suspension and colonies counted 3 weeks after 
growth. Colonies first appeared microscopically 10 days after seeding. Colonies of PLAG1-expressing cells 
remained small compared with colonies formed in PLAGL2-overexpressing cells where the cells were able to 
form colonies visible by the naked eye within 4 weeks of incubation (Fig. 4A). PLAGL2-expressing cells 
showed a colony-forming efficiency of 44%, whereas for PLAG1-expressing cells, 26% of seeded cells give rise 
to colonies (Fig. 4B). As expected, control cells failed to form such colonies. These results are summarized in 
Fig. 4B. 
 
Fig. 4. Overexpressed PLAG1 and PLAGL2 proteins are able to transform NIH3T3 cells. A, the mock-, PLAG1-, 
and PLAGL2-expressing NIH3T3 cells were used for focus-forming assay in medium containing 1% FCS or 10% 
FCS and for soft agar assay as described in "Materials and Methods." The photographs (×100 magnification) 
were taken on day 17 (focus assay) and day 25 (agar). B, table of the transforming properties of the NIH3T3 
transfectants: the number of foci per 300 000 puromycin-resistant cells. Average of three dishes from two 
independent infection experiments from cells grown in 1% FCS (1). Colonies have been counted 24 days after 
seeding and results are expressed as the ratio [(number of colonies formed/ number of plated cells) × 100] (2). 
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PLAGl- and PLAGL2-expressing NIH3T3 Cells Are Tumorigenic in Nude Mice. To determine whether the 
PLAG1- and PLAGL2-expressing NIH3T3 cells are tumorigenic in nude mice, cells were injected s.c. into 
afhymic NMRI-nu/nu mice and examined every week for tumor development. PLAG1-overexpressing cells 
induced rapidly growing tumors at the site of inoculation within 3 weeks, whereas tumor formation originating 
from cells overexpressing PLAGL2 was apparent a few days later. The mock-infected cells did not form any 
tumors during this time period (Fig. 4B). The mice were sacrificed after 5 weeks, and histological analysis 
identified tumors induced by the PLAG1-expressing cell line as fibrosarcomas (data not shown). Metastatic 
spread to other organs was not detected macroscopically during the time period of observation, but formation of 
microscopic metastasis cannot be ruled out. To verify whether PLAG1 and PLAGL2 were still expressed in the 
tumor, Northern blot analysis was performed. High levels of retroviral PLAG1 and PLAGL2 transcripts could be 
detected indicating that the tumors produced in the nude mice originated from the injected cells (data not shown). 
IGF-II Is Up-Regulated in Cells Overexpressing PLAG1 and PLAGL2. As shown in this report, PLAG1 and 
PLAGL2 have common transcriptional properties, because they activate transcription via binding to the same 
DNA consensus sequence. These observations indicate that PLAG1 and PLAGL2 could be transcription factors 
that regulate common genes. Because IGF-II has been identified as a putative target gene of PLAG1, we 
analyzed IgfII expression in PLAG1- and PLAGL2-overexpressing NIH3T3 cells. As shown in Fig. 5, a 
significant up-regulation of the major IgfII transcript was observed in cells overexpressing PLAG1 and PLAGL2 
(Fig. 5, lanes b and c). In addition, two minor transcripts of 2.0 and 1.2 kb, not present in the control cells, were 
also detected in cells overexpressing PLAG1 and PLAGL2. Moreover, PLAGL2 induces IgfII expression in the 
same range as PLAG1. To exclude the possibility that IgfII up-regulation in transformed NIH3T3 cells could be 
a secondary effect occurring in the process of the transformation, we determined whether IGF-II constitutes a 
transcriptional target for PLAG1 and PLAGL2. For this purpose, we generated PLAG-inducible cell lines where 
IGF-II expression could be analyzed shortly after induction of PLAG1 and PLAGL2 expression. We isolated 
independent clones, deriving from the human epithelial kidney 293 cell line, containing a zinc-inducible 
expression vector (11) encoding either PLAG1 (clones P1-8 and P1-32), PLAGL2 (clones PL2-2 and PL2-24), or 
the lacZ gene (clones B-1 and B-4). When clones were grown in the absence of zinc ions, no exogenous PLAG1 
or PLAGL2 could be detected, whereas only low level of β-gal were detected. On induction with 100 µM of 
ZnCl2, PLAG1 and PLAGL2 transcripts are efficiently synthesized. This expression results in a drastic up-
regulation of IGF-II expression (Fig. 6). This stimulation is specific, because it is not observed either with the β-
gal-expressing clones used as control or with the parental cell line. Furthermore, IGF-II up-regulation by 
PLAGL2 goes not via the induction of endogenous PLAG1 and vice versa, because no stimulation of endogenous 
PLAG1 and PLAGL2 transcript could be detected after zinc induction (data not shown). Moreover, the detected 
6-kb IGF-II transcript corresponds to the one deriving from the P3 promoter, which is known to contain PLAG1-
binding sites (4), as hybridization with a probe specific for the P3 transcript (exon 5 probe) detects the same 
band (data not shown). All of these results demonstrate a strong correlation between PLAG1, PLAGL2, and IGF-












Published in : Cancer Research (2002), vol. 62, pp. 1510-1517. 
Status : Postprint (Author’s version) 
 
Fig. 5. IgfΠ is up-regulated in NIH3T3 cells overexpressing PLAG1 and PLAGL2. Northern blot analysis of 
total RNA extracted from NIH3T3 cells infected with empty virus (a), human Flag-PLAG1 (b), and human Flag-
PLAGL2 (c) grown in 10% FCS. The membrane was hybridized with a 32P-labeled mouse IgfII probe specific for 
exon 6, a 32P-labeled PLAG1 probe, or a 32P-labeled PLAGL2 probe. Expression of β-actin transcript monitored 
the integrity and yield of RNA. 
 
Fig. 6. IGF-II is a direct target of PLAG1 and PLAGL2. Northern blot analysis of total RNA isolated from 
clones, deriving from the human epithelial kidney 293 cell line, containing a zinc-inducible expression vector 
(11) either for PLAG1 (clones P1-8 and P1-32), PLAGL2 (clones PL2-2 and PL2-24), or the lacZ gene (clones 
B-1, B21, and B-4) grown without (-) or with (+) 100 µM of ZnCl2. Blots were hybridized sequentially with 
32P-
labeled human PLAG1 cDNA, 32P-labeled human PLAGL2 cDNA, 32P-labeled lacZ, 32P-labeled human IGF-II 




Pleomorphic adenomas of the salivary glands are characterized by recurrent translocations that lead to promoter 
substitution between PLAG1, a gene mainly expressed in fetal tissue, and more broadly expressed genes. The 
replacement of the PLAG1 promoter, inactive in adult salivary glands, by a strong promoter derived from the 
translocation partner leads to ectopic expression of PLAG1 in tumoral cells (1). The question remains whether 
ectopic expression of PLAG1 leads to the development of neoplasias, in this way acting as an oncogene. To 
approach this question, we determined the in vitro transforming capacity of PLAG1 in NIH3T3 cells. The 
transformation of NIH3T3 cells is a sensitive bioassay for the detection of transforming genes (17). Since we 
also show here that PLAGL2 has indistinguishable DNA-binding capacities compared with PLAG1, we were 
interested to see if PLAGL2 has the same transforming effect in vitro. We found that cell lines producing high 
levels of PLAG1 or PLAGL2 are able to proliferate in medium containing only 1% serum suggesting that these 
genes partially abrogate the serum requirement for the growth of NIH3T3 cells. Moreover, these cells expressed 
the typical markers of neoplastic transformation; foci appeared within 2-3 weeks with a similar morphology to 
that described previously in transfection studies involving integrated c-ets1 DNA in NIH3T3 cells (18). In 
addition, cells overexpressing PLAG1 and PLAGL2 show anchorage-independent growth and are able to induce 
tumors in nude mice. These observations allow us to define the PLAG1 and PLAGL2 family members as proto-
oncogenes with mitogenic and transforming potential when overexpressed in NIH3T3 cells. On the contrary, the 
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PLAGL1 family member has been shown to inhibit tumor cell proliferation through induction of both apoptosis 
and cell cycle arrest, in this way acting as a tumor suppressor gene (8). These data together with our own indicate 
that the three members of the PLAG family are involved in cellular transformation in distinct ways. 
The in vitro transformation data are consistent with the role of PLAG1 and PLAGL1 described in tumorigenesis. 
Indeed, PLAGL1 prevents the proliferation of tumor cells in vitro (8, 19), which correlates with the complete or 
partial loss of PLAGL1 expression observed in breast tumor cell lines and primary breast tumors harboring loss 
of chromosomal material in the 6q24-25 region. This suggests that lost of expression of PLAGL1 in premalignant 
epithelial cells can contribute to the initiation or progression of breast tumors (9). For PLAGL1, the in vitro data 
indicate that PLAG1 is able to induce cellular transformation when overexpressed. This correlates with in vivo 
data, because PLAG1 ectopic expression was observed not only in pleomorphic adenomas of the salivary gland 
but also in other kinds of tumors. Indeed, PLAG1 promoter swapping has been discovered recently to also be a 
critical event in lipoblastomas with 8q12 rearrangements (20). Ectopic expression has also been found in other 
tumors such as uterine leiomyoma, leiomyosarcomas, and smooth muscle tumors, and in pleomorphic adenomas 
with 12q15 translocations and normal karyotype (3). This emphasizes the importance of PLAG1 overexpression 
in tumorigenesis. Regarding PLAGL2, thus far we have no evidence for aberrant expression in any type of 
tumor. However, chromosome 20q11-12 aberrations, in the region where PLAGL2 is located, are a recurrent 
abnormality in malignant myeloid disorders. By screening the tumor databank of the Center for Human Genetics 
in Leuven, 20q11-12 translocations were found in patients who developed myeloid diseases. Fluorescence in situ 
hybridization analysis revealed that three patients present translocations in the PLAGL2 region. Additional 
investigations are still required to determine whether PLAGL2 overexpression could play a role in the 
development of this disease. 
The mechanisms by which PLAG1 and perhaps PLAGL2 proteins induce tumorigenesis are not yet known. 
Because PLAG1 and PLAGL2 are genuine transcription factors, deregulation of PLAG expression possibly 
leads to deregulation of particular target genes involved in mitogenic stimulation, tissue remodeling, and 
vascularization associated with neoplasias. In this report we show that IgfΠ is not only up-regulated in NIH3T3 
cells expressing PLAG1 and PLAGL2, but IGF-II expression is also immediately activated on PLAG1 and 
PLAGL2 expression by using PLAG1 and PLAGL2 zinc-inducible human 293 kidney cell lines. These results 
suggest that IGF-II is a target gene of PLAG1 and PLAGL2. IGF-II is a peptide fetal growth factor that plays an 
important role during embryonic development and carcinogenesis (21). Interestingly, the pattern of expression of 
PLAG1 and IGF-II is similar because expression is high during fetal life and decreases drastically after birth (22, 
23).2 These results link abnormal PLAG1 and PLAGL2 expression with the activation of the IGF-II mitogenic 
signaling, which is mainly mediated via the IGF-I-R. Activation of the IGF-I-R can increase mitogenesis, which 
is mediated primarily by activating the Ras/Raf/ mitogen-activated protein kinase pathway (24). This provides an 
explanation for the ability of PLAG1 and PLAGL2 to stimulate neoplastic transformation. This hypothesis is 
supported by transformation studies performed on R- cells. R- cells are 3T3 cells derived from mouse embryos 
with a targeted disruption of the IGF-I-R genes (25, 26). Because the transforming effect of IGF-II is believed to 
be mainly mediated via this receptor, we were wondering if PLAG1 and PLAGL2 still could transform these R- 
cells. When focus-forming assay was performed on R- cells overexpressing PLAG1 or PLAGL2, cells could not 
form foci anymore (data not shown). We can now propose a model that ectopic expression of PLAG1 and 
PLAGL2 leads to the reactivation of IGF-II transcription, which results in a restarted developmental program 
with concomitant loss of differentiation, the typical hallmark of any tumor. This model is supported by 
immunohistochemistry on pleomorphic adenomas of the salivary gland. It revealed that the most differentiated 
cells of the inner tubuloductal epithelium only sporadically express PLAG1, whereas less differentiated cells of 
the outer tubuloductal epithelium in the tumor were strongly PLAG1 positive (27). Moreover, undifferentiated 
cells in the tumor exhibited up-regulation of the antiapoptotic Bc12 protein, a downstream element in the 
cascade of the antiapoptotic activity mediated via the IGF-I-R. Indeed, the transforming activity of the IGF-I-R 
depends on its potent antiapoptotic activity in addition to its mitogenic effect (28, 29). Additional investigations 
will be performed to analyze which level of the IGF system is influenced in PLAG1-mediated tumorigenesis. 
As shown here, all of the three members of the PLAG family seem to be involved in tumorigenesis but in distinct 
ways. This difference in function is reflected in the DNA-binding capacity, because we found that the PLAG 
proteins display different binding characteristics. Indeed, PLAG1 and PLAGL2 bind to a bipartite motif 
containing a Core and the G-cluster, whereas PLAGL1 binds only to an extended Core motif (Fig. 7B). This 
difference can be explained by the fact that the finger 3 of PLAGL1 is not directly involved in DNA recognition, 
whereas in PLAG1 and PLAGL2, it interacts with the G-cluster. This difference in binding specificity is quite 
surprising, as the zinc finger domain of the three PLAG proteins is quite highly conserved (74% identity; Fig. 
                                                        
2
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7A). The highest homology is found in fingers 6 and 7, responsible for binding to the Core motif. This can 
explain why these three proteins recognize a similar Core sequence (Fig. 7B). In contrast, fingers 2 to 5 shows 
much less conservation except in the key residues (highlighted in Fig. 7A). These residues typically make key 
base contacts that are responsible for defining sequence specificity (reviewed in Ref. 30). Finger 3, which is 
critical for the binding to the G-cluster, is surprisingly well conserved in PLAGL1, notably in the key residues 
(see Fig. 7A). This indicates that these key residues, although essential for binding, are not sufficient to 
determine specificity and that other amino acids also play a role. 
It is interesting to note that PLAG1 undergoes extensive alternative splicing, notably of exon 4, which contains 
the first ATG (31). This will lead to different isoforms starting either at methionine 83 or methionine 100. This is 
assumed to have considerable consequences, because the isoform starting at position 100 does not contain finger 
3 and, thus, does not recognize the G-cluster, giving rise to a splice form with different DNA binding specificity. 
This is reminiscent of the situation of the Wilms tumor 1 gene (32) and the PR-domain family genes (33) where 
the different isoforms have different DNA specificities and even opposing effects on tumorigenicity. 
On the basis of our DNA-binding studies, we can also hypothesize that the difference in DNA-binding 
specificity described here could be one of the reasons PLAGL1 behaves as a tumor suppressor gene in contrast to 
the other two family members. PLAGL1 probably regulates a different set of target genes, which results in a 
different response. Regarding PLAG1 and PLAGL2, their similar binding capacities suggest that they regulate 
the expression of the same target genes, and IGF-II is the first example of such a common target gene. This 
discovery of IGF-II as a target in pleomorphic adenomas is an important step in the treatment of this disease, 
because we can envision that drugs designed to decrease the IGF-II levels in other types of tumors could be also 
used for the treatment of pleomorphic adenomas. 
Fig. 7. Comparison of the zinc finger motifs in the three PLAG proteins. A, alignment of the seven zinc fingers 
motifs in PLAG1, PLAGL1, and PLAGL2. Only the amino acids different in PLAGL1 and PLAGL2 are 
indicated. The key residues (highlighted) are defined on the basis that each finger module folds to form a 
compact ββa structure with the α-helix fitting in the major grove. (reviewed in Ref. 30). Residues -1, +2, +3 and 
+6 (numbering with respect to the start of the α-helix) typically make key base contacts that are responsible for 
defining sequence specificity. B, comparison of the DNA-binding consensus sequence of PLAG1 and PLAGL1. 
The consensus reported here for PLAG1 is not the minimal consensus GRGGC(N)7RGGK as described 





Published in : Cancer Research (2002), vol. 62, pp. 1510-1517. 
Status : Postprint (Author’s version) 
 
ACKNOWLEDGMENTS 
We thank Prof. Dr. B. Van Damme for the histological analysis of the tumors from the nude mice, Jan Cools 
from the CME KULeuven for providing the pMSCVpuro and pIK6.1 Ecopac vector and technical advice, N. 
Agten and M. Willems for the technical assistance, P. E. Holthuizen for her kind gift of the IGF-II exon5 probe, 
Dr. J. Rossant for her kind gift of the SDKlacZpA vector, Bert Vogelstein for the kind gift of the pSAR-MT-βgal 
vector, and Dr. Renato Baserga from the Kimmel Cancer Center at the Thomas Jefferson University in 
Philadelphia, PA, for providing the R- cells. Additionally, we thank Neil Taylor for critical review of the 
manuscript. 
REFERENCES 
1.  Kas, K., Voz, M. L., Roijer, E., Astrom, A. K., Meyen, E., Stenman, G., and Van de Ven, W. J. Promoter swapping between the genes for 
a novel zinc finger protein and β-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat. Genet.. 15: 170-174, 1997. 
2.  Voz, M. L., Astrom, A. K., Kas, K., Mark, J., Stenman, G., and Van de Ven, W. J. The recurrent translocation t(5;8)(p13;q12) in 
pleomorphic adenomas results in up-regulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene, 16: 1409-1416, 
1998. 
3.  Astrom, A. K., Voz, M. L., Kas, K., Roijer, E., Wedell, B., Mandahl, N., Van de Ven, W., Mark, J., and Stenman, G. Conserved 
mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SΠ as a new 
fusion partner gene. Cancer Res., 59: 918-923, 1999. 
4.  Voz, M. L., Agten, N. S., Van de Ven, W. J., and Kas, K. PLAG1, the main translocation target in pleomorphic adenoma of the salivary 
glands, is a positive regulator of IGF-Π, Cancer Res. 60: 106-113, 2000. 
5.  Kas, K., Voz, M. L., Hensen, K., Meyen, E., and Van de Ven, W. J. M. Transcriptional activation capacity of the novel PLAG family of 
zinc finger proteins. J. Biol. Chem., 273: 23026-23032, 1998. 
6.  Abdollahi, A., Roberts, D., Godwin, A. K., Schultz, D. C, Sonoda, G., Testa, J. R., and Hamilton, T. C. Identification of a zinc-finger 
gene at 6q25: a chromosomal region implicated in development of many solid tumors. Oncogene, 14: 1973-1979, 1997. 
7.  Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, J., and Journot, L. Regulation of apoptosis and cell cycle 
arrest by Zacl, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J., 16: 2814-2825, 1997. 
8.  Varrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., Spengler, D., and Journot, L. hZAC encodes a 
zinc finger protein with antiproliferative properties and maps to a chromosomal region frequently lost in cancer. Proc. Natl. Acad. Sci. USA, 
95: 8835-8840, 1998.  
9. Bilanges, B., Varrault, A., Basyuk, E., Rodriguez, C., Mazumdar, A., Pantaloni, C., Bockaert, J., Theillet, C., Spengler, D., and Journot, L. 
Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene, 18: 3979-3988, 
1999. 
10.  Hawley, R. G., Lieu, F. H., Fong, A. Z., and Hawley, T. S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther., 1: 
136-138, 1994. 
11.  Morin, P. J., Vogelstein, B., and Kinzler, K. W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA, 93: 7950-
7954, 1996. 
12.  Nordeen, S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques, 6: 454-458, 1988. 
13.  Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. 
Anal. Biochem., 162: 156-159, 1987. 
14.  Dull, T. J., Gray, A., Hayflick, J. S., and Ullrich, A. Insulin-like growth factor II precursor gene organization in relation to insulin gene 
family. Nature (Lond.), 310: 777-781, 1984. 
15.  Sanchez, M. P., Silos-Santiago, I., Frisen, J., He, B., Lira, S. A., and Barbacid, M. Renal agenesis and the absence of enteric neurons in 
mice lacking GDNF. Nature (Lond.), 382: 70-73, 1996. 
16.  Ikeda, K., and Kawakami, K. DNA binding through distinct domains of zinc-finger-homeodomain protein AREB6 has different effects 
on gene transcription. Eur. J. Biochem., 233: 73-82, 1995. 
17.  Jainchill, J. L., Aaronson, S. A., and Todaro, G. J. Murine sarcoma and leukemia viruses: assay using clonal lines of contact -inhibited 
mouse cells. J. Virol., 4: 549-553, 1969. 
 
Published in : Cancer Research (2002), vol. 62, pp. 1510-1517. 
Status : Postprint (Author’s version) 
 
18.  Seth, A., and Papas, T. S. The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. Oncogene, 5: 1761-1767, 
1990. 
19.  Abdollahi, A., Bao, R., and Hamilton, T. C. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor 
ligands and encodes a nuclear zinc-finger protein. Oncogene, 18: 6477-6487, 1999. 
20.  Hibbard, M. K., Kozakewich, H. P., Dal Cin, P., Sciot, R., Tan, X., Xiao, S., and Fletcher, J. A. PLAG1 fusion oncogenes in 
lipoblastoma. Cancer Res., 60: 4869-4872, 2000. 
21.  Toretsky, J. A., and Helman, L. J. Involvement of IGF-II in human cancer. J. Endocrinol., 149: 367-372, 1996. 
22.  Roberts, C. T., Jr., Brown, A. L., Graham, D. E., Seelig, S., Berry, S., Gabbay, K. H., and Rechler, M. M. Growth hormone regulates the 
abundance of insulin-like growth factor I RNA in adult rat liver. J. Biol. Chem., 261: 10025-10028, 1986. 
23.  Brown, A. L., Graham, D. E., Nissley, S. P., Hill, D. J., Strain, A. J., and Rechler, M. M. Developmental regulation of insulin-like 
growth factor II mRNA in different rat tissues. J. Biol. Chem., 261: 13144-50, 1986. 
24.  LeRoith, D., Werner, H., Neuenschwander, S., Kalebic, T., and Helman, L. J. The role of the insulin-like growth factor-I receptor in 
cancer. Ann. N. Y. Acad. Sci., 766: 402-408, 1995. 
25.  Sell, C, Dumenil, G., Deveaud, C, Miura, M., Coppola, D., DeAngelis, T., Rubin, R., Efstratiadis, A., and Baserga, R. Effect of a null 
mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol., 14: 
3604-3612, 1994. 
26.  Sell, C, Rubini, M., Rubin, R., Liu, J. P., Efstratiadis, A., and Baserga, R. Simian virus 40 large tumor antigen is unable to transform 
mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA, 90: 11217-11221, 1993. 
27.  Debiec-Rychter, M., Van Valckenborgh, I., Van Den Broeck, C, Hagemeijer, A., Van De Ven, W. J., Kas, K., Van Damme, B., and Voz, 
M. L. Histologic localization of plag1 (pleomorphic adenoma gene 1) in pleomorphic adenoma of the salivary gland: cytogenetic evidence of 
common origin of phenotypically diverse cells. Lab. Investig., 81: 1289-1297, 2001. 
28.  Rodriguez-Tarduchy, G., Collins, M. K., Garcia, I., and Lopez-Rivas, A. Insulin-like growth factor-I inhibits apoptosis in IL-3-
dependent hemopoietic cells. J. Immunol., 149: 535-540, 1992. 
29.  Resnicoff, M., Burgaud, J. L., Rotman, H. L., Abraham, D., and Baserga, R. Correlation between apoptosis, tumorigenesis, and levels of 
insulin-like growth factor I receptors. Cancer Res., 55: 3739-3741, 1995. 
30.  Choo, Y., and Klug, A. Physical basis of a protein-DNA recognition code. Curr. Opin. Struct. Biol., 7: 117-125, 1997. 
31.  Queimado, L., Lopes, C, Du, F., Martins, C, Bowcock, A. M., Soares, J., and Lovett, M. Pleomorphic adenoma gene 1 is expressed in 
cultured benign and malignant salivary gland tumor cells. Lab. Investig., 79: 583-589, 1999. 
32.  Menke, A. L., Riteco, N., van Ham, R. C., de Bruyne, C., Rauscher, F. J. d., van der Eb, A. J., and Jochemsen, A. G. Wilms' tumor 1 
splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells. Oncogene, 12: 537-546, 1996. 
33.  Jiang, G. L., and Huang, S. The yin-yang of PR-domain family genes in tumorigenesis. Histol. Histopathol., 15: 109-117, 2000. 
